Compare Stocks: PEPG, CLYM, CADL, and SLN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.84 +2.7%	$11.16	$4.35 ▼ $14.00	$829.02M	-0.48	1.50 million shs	447,399 shs
CLYM Climb Bio	$14.79 +3.8%	$14.24	$1.54 ▼ $18.33	$849.48M	0.09	999,920 shs	391,534 shs
PEPG PepGen	$2.98 -0.2%	$2.59	$1.31 ▼ $7.80	$206.05M	1.97	1.05 million shs	361,094 shs
SLN Silence Therapeutics	$13.06 +0.3%	$12.36	$4.19 ▼ $17.58	$788.45M	1.45	563,465 shs	466,956 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	-17.45%	-9.98%	+23.25%	+120.25%
CLYM Climb Bio	0.00%	-8.18%	-12.74%	+24.02%	+533.33%
PEPG PepGen	0.00%	-4.18%	-0.33%	+94.77%	+101.35%
SLN Silence Therapeutics	0.00%	-10.76%	-5.10%	+86.00%	+188.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.84 +2.7%	$11.16	$4.35 ▼ $14.00	$829.02M	-0.48	1.50 million shs	447,399 shs
CLYM Climb Bio	$14.79 +3.8%	$14.24	$1.54 ▼ $18.33	$849.48M	0.09	999,920 shs	391,534 shs
PEPG PepGen	$2.98 -0.2%	$2.59	$1.31 ▼ $7.80	$206.05M	1.97	1.05 million shs	361,094 shs
SLN Silence Therapeutics	$13.06 +0.3%	$12.36	$4.19 ▼ $17.58	$788.45M	1.45	563,465 shs	466,956 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	-17.45%	-9.98%	+23.25%	+120.25%
CLYM Climb Bio	0.00%	-8.18%	-12.74%	+24.02%	+533.33%
PEPG PepGen	0.00%	-4.18%	-0.33%	+94.77%	+101.35%
SLN Silence Therapeutics	0.00%	-10.76%	-5.10%	+86.00%	+188.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.64	Moderate Buy	$19.29	78.37% Upside
CLYM Climb Bio	3.00	Buy	$26.92	81.11% Upside
PEPG PepGen	2.71	Moderate Buy	$11.50	289.17% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	305.55% Upside

Current Analyst Ratings Breakdown

Latest PEPG, CLYM, CADL, and SLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	CLYM Climb Bio	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00
8/28/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $24.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$2.14 per share	N/A
SLN Silence Therapeutics	$560K	1,418.38	N/A	N/A	$1.32 per share	9.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest PEPG, CLYM, CADL, and SLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.38	16.09	16.09
CLYM Climb Bio	N/A	31.45	31.45
PEPG PepGen	N/A	13.36	13.36
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CLYM Climb Bio	69.76%
PEPG PepGen	58.01%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
CLYM Climb Bio	2.60%
PEPG PepGen	1.30%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
PEPG PepGen	30	69.26 million	68.36 million	Not Optionable
SLN Silence Therapeutics	88	60.21 million	58.40 million	Not Optionable

PEPG, CLYM, CADL, and SLN Headlines

Recent News About These Companies

Seven Fleet Capital Management LP Sells 96,652 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

September 5, 2026 | marketbeat.com

Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $53.50

September 5, 2026 | americanbankingnews.com

Silence Therapeutics to Participate in Three September Investor Conferences

September 2, 2026 | cityam.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 5.8% - Should You Buy?

September 1, 2026 | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 31, 2026 | marketbeat.com

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

August 26, 2026 | marketbeat.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?

August 18, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SLN Q3 Earnings?

August 18, 2026 | marketbeat.com

Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN)

August 17, 2026 | marketbeat.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints

August 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, CLYM, CADL, and SLN Company Descriptions

Candel Therapeutics NASDAQ:CADL

$10.84 +0.29 (+2.70%)

As of 01:19 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Climb Bio NASDAQ:CLYM

$14.79 +0.54 (+3.79%)

As of 01:20 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

PepGen NASDAQ:PEPG

$2.98 -0.01 (-0.17%)

As of 01:19 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$13.06 +0.04 (+0.31%)

As of 01:20 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, CLYM, CADL, and SLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, CLYM, CADL, and SLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, CLYM, CADL, and SLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, CLYM, CADL, and SLN Company Descriptions

Candel Therapeutics NASDAQ:CADL

Climb Bio NASDAQ:CLYM

PepGen NASDAQ:PEPG

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, CLYM, CADL, and SLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, CLYM, CADL, and SLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, CLYM, CADL, and SLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, CLYM, CADL, and SLN Company Descriptions

Candel Therapeutics NASDAQ:CADL

Climb Bio NASDAQ:CLYM

PepGen NASDAQ:PEPG

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools